Biotech | August 28, 2022
Moderna files for emergency use of BA.4/BA.5 Omicron booster
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Philips AI-powered interventional and diagnostic smart systems enhances diagnostic confidence, drive greater efficiency, and improve patient outcomes
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
Fund VI will focus on investments in industrials and healthcare businesses with proven technologies and solutions positioned to deliver high performance and value-add to their customers
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Therapy recently approved in Canada under the brand name KORSUVA
Subscribe To Our Newsletter & Stay Updated
